Southampton University Hospital Extends Monitor Contract
19-09-2006
LiDCO Group plc (AIM: LID), the cardiovascular monitoring company, announces the purchase of an additional 6 LiDCOplus Monitors by Southampton University Hospital Trust. The contract is in excess of £80K and delivery was made on 8 September 2006.
Southampton University Hospital Trust (the “Trust”) now has a total of 14 LiDCOplus monitors in use across the hospital in a variety of different clinical locations including: intensive care, post cardiac surgery and neuro intensive care. During the evaluation process, competing technologies were evaluated across several criteria including clinical utility and cost effectiveness. LiDCO scored highly in all areas. Having evaluated all of the alternative devices on market in the UK, LiDCO was regarded as the best and most accurate and has allowed the hospital to further phase out the use of the older invasive catheter based product.
Dr Mike Herbertson Consultant Cardiac Anesthetist said: “Southampton University Hospital Trust have expanded their facility for the care of patients with heart disease as a result of a £60 million investment from NHS funds. An important part of the expansion has been the creation of a new critical care complex. Within the critical care complex the Trust has purchased new equipment to improve care for patients with heart disease. A central part of this new equipment has been the purchase of six state of the art monitors from LiDCO Group Plc. The LiDCOplus monitors we have purchased provide crucial information for the care of patients after heart surgery. We have used these monitors for some of our patients after heart surgery over the last few years. As a result of this purchase we plan to use these monitors as a standard part of the care of all patients after heart surgery. We expect the information we see from these monitors will allow us to further improve the outcomes for our cardiac surgery patients.”
Commenting on this announcement, Terry O’Brien, Chief Executive of LiDCO, said: “We are delighted that Southampton Cardiac unit has chosen our technology as its minimally invasive hemodynamic monitor of choice. This is particularly rewarding as it follows on from our technology being used in Southampton’s General and Neuro intensive care units. We look forward very much to working with the doctors and nursing and technical staff there to ensure a smooth implementation and use of our technology in order to continue to enhance patient care. We are grateful to the staff and hospital trust management for the faith they have in our company and technology. The progressive and wider adoption by the Trust and the NHS generally of LiDCO’s minimally invasive monitoring technology is driven by a desire to continually improve clinical and surgical outcomes.”
LiDCO will announce its interim results for the six months to 31 July 2006 on 18 October 2006.
| For further information please contact: |
|
| |
|
| LiDCO Group Plc |
|
Terry O'Brien (CEO)
Hugh McGarel-Groves (FD) |
Tel: +44 (0)20 7749 1500 |
Financial PR: Buchanan Communications |
|
| Tim Anderson, James Strong |
Tel: +44 (0)20 7466 5000 |
Notes to Editors
About LiDCO Group Plc
LiDCO is a UK-based AIM-traded developer, manufacturer and leading supplier of minimally invasive, computer-based hemodynamic monitoring equipment and disposables used primarily for the management of critical care and cardiovascular risk hospital patients. Use of LiDCO’s technology has been shown to significantly reduce the complications (particularly infections) and costs associated with major surgery. The technology was invented in the Department of Applied Physiology based at St Thomas’ Hospital, London.
The Company’s manufacturing facility is in London N1, UK and its products are:
LiDCOplus and PulseCO monitors: computer-based platforms for displaying and management of a range of real-time, continuous hemodynamic parameters including cardiac output, oxygen delivery and fluid volume;
LiDCO disposables: used in conjunction with the LiDCOplus Monitor to accurately determine cardiac output in a minimally-invasive manner.
Distribution Network:
The Company has now achieved registration of its products in 14 markets in Europe, together with the USA, Brazil and Japan. It sells direct in the USA and UK, and elsewhere through a worldwide network of specialty critical care distributors
|